SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Sep 25, 2026	Sep 25, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 13, 2026	Aug 13, 2026	View filing
10-Q	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Aug 4, 2026	Aug 4, 2026	View filing
4	Jul 29, 2026	Jul 29, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
SC 13G	Apr 29, 2026	Apr 29, 2026	View filing
ARS	Apr 17, 2026	Apr 17, 2026	View filing
DEFA14A	Apr 17, 2026	Apr 17, 2026	View filing
DEF 14A	Apr 17, 2026	Apr 17, 2026	View filing
4	Apr 6, 2026	Apr 6, 2026	View filing
4	Apr 6, 2026	Apr 6, 2026	View filing
4	Apr 6, 2026	Apr 6, 2026	View filing
4	Apr 6, 2026	Apr 6, 2026	View filing
4	Apr 6, 2026	Apr 6, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing

About Beam Therapeutics Inc.

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Cambridge, MA

540 employees

www.beamtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Evans

View full financials